Prognostic value of PCSK9 levels in patients with acute coronary syndromes

Gencer, Baris; Montecucco, Fabrizio; Nanchen, David; Carbone, Federico; Klingenberg, Roland; Vuilleumier, Nicolas; Aghlmandi, Soheila; Heg, Dik; Räber, Lorenz; Auer, Reto; Jüni, Peter; Windecker, Stephan; Lüscher, Thomas F; Matter, Christian M; Rodondi, Nicolas; Mach, François

doi:10.1093/eurheartj/ehv637

Scientific article

English

Prognostic value of PCSK9 levels in patients with acute coronary syndromes

ContributorsGencer, Baris; Montecucco, Fabrizio; Nanchen, David; Carbone, Federico; Klingenberg, Roland; Vuilleumier, Nicolas; Aghlmandi, Soheila; Heg, Dik; Räber, Lorenz; Auer, Reto; Jüni, Peter; Windecker, Stephan; Lüscher, Thomas F; Matter, Christian M; Rodondi, Nicolas; Mach, François

Published inEuropean heart journal, vol. 37, p. 546-553

Publication date2016

Abstract

Proprotein convertase subtilisin kexin 9 (PCSK9) is an emerging target for the treatment of hypercholesterolaemia, but the clinical utility of PCSK9 levels to guide treatment is unknown. We aimed to prospectively assess the prognostic value of plasma PCSK9 levels in patients with acute coronary syndromes (ACS).

Affiliation entities

Research groups

Citation (ISO format)

GENCER, Baris et al. Prognostic value of PCSK9 levels in patients with acute coronary syndromes. In: European heart journal, 2016, vol. 37, p. 546–553. doi: 10.1093/eurheartj/ehv637

Article (Published version)

Identifiers

PID : unige:84039
DOI : 10.1093/eurheartj/ehv637
PMID : 26655339

Journal ISSN0195-668X

625views

2downloads

Creation03/02/2016 15:01:00

First validation03/02/2016 15:01:00

Update time24/01/2025 13:58:29

Status update24/01/2025 13:58:29

Last indexation24/01/2025 14:02:10

Archive ouverte UNIGE

Prognostic value of PCSK9 levels in patients with acute coronary syndromes

Technical informations